Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlos Conde has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elevated MPS1 converts the fibrous corona into a source of chromosomal instability in colon cancer

    by Ana Pinto-Teixeira, André Oliveira, Gonçalo Gouveia, Ana Sousa, Jessica Roelands, Marco Grillo, Sergi Rodriguez-Calado, Carlos Resende, Helena Xavier-Ferreira, Mariana Osswald, et al.

    Chromosomal instability (CIN), characterised by recurrent chromosome mis-segregation, fuels intratumour heterogeneity and tumour evolution. Yet, its proximal molecular causes remain ill-defined. Tumour-scale genomic and transcriptomic analyses associate MPS1 overexpression with CIN in colon carcinomas. Consistently, CIN + patient-derived colon cancer cells (PCCCs) display elevated MPS1, frequent merotelic kinetochore-microtubule attachments and lagging chromosomes that are suppressed by partial MPS1 inhibition. Conversely, ectopic MPS1 overexpression in otherwise stable near-diploid cells phenocopies these defects, inducing micronuclei formation and karyotypic divergence. Mechanistically, MPS1 overactivity maintains ROD phosphorylation at Thr13/Ser15, continuously sustaining fibrous corona assembly despite mature end-on attachments. 3D-STED microscopy reveals split-interface configurations in which microtubules from opposing poles engage the canonical outer-kinetochore surface and a spatially distinct corona domain, explaining how merotely forms and persists into anaphase. Disrupting corona assembly restores chromosome segregation fidelity in MPS1-overexpressing RPE-1 cells and in CIN + PCCCs. Together, our findings establish MPS1 overexpression as a driver of CIN and uncover how oncogenic transcriptional rewiring of mitotic signalling converts a transient microtubule-capture structure into a pathological source of merotely and chromosome mis-segregation in colon cancer.

  • Polo kinase inhibits protein phosphatase 1 to promote the spindle assembly checkpoint and prevent aneuploidy

    by Margarida Moura, João Barbosa, Inês Pinto, Nelson Leça, Sofia Cunha-Silva, Arianna Esposito Verza, Paulo D. Pedroso, Sarah Lemaire, Joana Duro, Miguel Simoes-Da-Silva, et al.


  • Open Access

    Artificial intelligence‐driven closed‐loop devices in sudden unexpected death in epilepsy prediction and prevention: Insights from persons with epilepsy and caregivers

    by João Ferreira, Miguel França, Mariana Cardoso Regalo, Mariana Rei, Ricardo Peixoto, José Ángel Aibar, Torie Robinson, Ricardo Matias, Fabrice Duprat, Massimo Mantegazza, et al.

    Objective: The absence of strategies for predicting and preventing sudden unexpected death in epilepsy (SUDEP) is intertwined with the lack of studies measuring users' attitudes toward potential innovative interventions. The NEUROSENSE Project ( http://www.neurosense‐project.eu ) aims to evaluate novel SUDEP‐predictive neuroendocrine biomarkers in interstitial fluid. The ultimate aim is to develop an artificial intelligence‐driven closed loop device (AI‐CLD) prototype that can recognize life‐threatening seizures and prevent SUDEP through automatic intervention. The current study introduces the potential use of AI‐CLDs in SUDEP prediction and prevention, while assessing person with epilepsy (PWE) and caregiver (CG) attitudes toward AI‐CLD adoption and implementation. Methods: A qualitative study was conducted through three focus groups involving PWEs and CGs. Participants were recruited through the NEUROSENSE Patient Advisory Board, with discussions facilitated through a semistructured interview guide. The study followed grounded theory and qualitative content analysis methods. Data were collected between October 2024 and February 2025, with all sessions transcribed and analyzed. Results: Three main areas emerged from the analysis: expectations of AI‐CLDs for SUDEP prediction and prevention, decision‐making processes involving AI use in health care, and barriers and facilitators to AI‐CLD adoption. PWEs and CGs generally expressed positive attitudes toward AI‐CLDs, supporting automatic data sharing with health care providers and real‐time alerts. However, concerns about AI accuracy, overreliance on automation, and the need for control over interventions were raised. Both groups preferred wearable devices over implanted solutions, emphasizing comfort and discretion as critical factors for adoption. Significance: This study highlights the potential of AI‐CLDs in improving the prediction and prevention of SUDEP, showing promise for enhancing patient safety through real‐time monitoring and interventions. The findings underscore the importance of user‐centered design in device development, emphasizing comfort, control over interventions, and integration into daily life. This research provides insights useful for future development aiming to improve PWE and CG confidence in using AI technologies for epilepsy care and risk management.


  • Proximity-based activation of AURORA A by MPS1 potentiates error correction

    by Nelson Leça, Francisca Barbosa, Sergi Rodriguez-Calado, Arianna Esposito Verza, Margarida Moura, Paulo D. Pedroso, Inês Pinto, Elena Artes, Tanja Bange, Claudio E. Sunkel, et al.


  • Open Access

    POLO kinase inhibits Protein Phosphatase 1 to promote the Spindle Assembly Checkpoint and prevent aneuploidy

    by Margarida Moura, João Barbosa, Inês Pinto, Nelson Leça, Sofia Cunha-Silva, Arianna Esposito Verza, Paulo D. Pedroso, Sarah Lemaire, Joana Duro, Miguel Silva, et al.

    SUMMARY: Protein phosphatase 1 (PP1) is essential for spindle assembly checkpoint (SAC) silencing and mitotic exit, but its regulation during mitosis remains ill-defined. Here, we demonstrate in vitro and in Drosophila cells that the mitotic kinase POLO phosphorylates PP1α87B at a conserved residue (T286) within a pocket implicated in the recognition of RVxF-containing target proteins. Phosphorylation of T286 inhibits PP1α87B binding to the RVxF motif of the SAC kinase MPS1, dampening the dephosphorylation of MPS1 T-loop. Phosphorylation of T286 is dynamically regulated during mitosis. It occurs at unattached/tensionless kinetochores and decreases as chromosomes congress. Expression of phosphomimetic PP1α87B T286D prevents MPS1 inactivation in metaphase and causes a SAC-dependent delay of anaphase onset. Conversely, an unphosphorylatable PP1α87B T286A mutant impairs MPS1 activation at unattached kinetochores and weakens the SAC. In vivo , larval neuroblasts expressing PP1α87B T286 phosphomutants exhibit frequent chromosome mis-segregation and aneuploidy. Thus, our findings identify POLO-mediated phosphorylation of PP1α87B as a critical regulatory strategy that fine-tunes phosphatase activity to ensure a robust and timely SAC and prevent genome instability.


  • Open Access

    User involvement in the design and development of medical devices in epilepsy: A systematic review

    by João Ferreira, Ricardo Peixoto, Lígia Lopes, Sándor Beniczky, Philippe Ryvlin, Carlos Conde, João Claro

    Objective: This systematic review aims to describe the involvement of persons with epilepsy (PWE), healthcare professionals (HP) and caregivers (CG) in the design and development of medical devices is epilepsy.Methods: A systematic review was conducted, adhering to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Eligibility criteria included peer‐reviewed research focusing on medical devices for epilepsy management, involving users (PWE, CG, and HP) during the MDD process. Searches were performed on PubMed, Web of Science, and Scopus, and a total of 55 relevant articles were identified and reviewed.Results: From 1999 to 2023, there was a gradual increase in the number of publications related to user involvement in epilepsy medical device development (MDD), highlighting the growing interest in this field. The medical devices involved in these studies encompassed a range of seizure detection tools, healthcare information systems, vagus nerve stimulation (VNS) and electroencephalogram (EEG) technologies reflecting the emphasis on seizure detection, prediction, and prevention. PWE and CG were the primary users involved, underscoring the importance of their perspectives. Surveys, usability testing, interviews, and focus groups were the methods used for capturing user perspectives. User involvement occurs in four out of the five stages of MDD, with production being the exception.Significance: User involvement in the MDD process for epilepsy management is an emerging area of interest holding a significant promise for improving device quality and patient outcomes. This review highlights the need for broader and more effective user involvement, as it currently lags in the development of commercially available medical devices for epilepsy management. Future research should explore the benefits and barriers of user involvement to enhance medical device technologies for epilepsy.Plain Language Summary: This review covers studies that have involved users in the development process of medical devices for epilepsy. The studies reported here have focused on getting input from people with epilepsy, their caregivers, and healthcare providers. These devices include tools for detecting seizures, stimulating nerves, and tracking brain activity. Most user feedback was gathered through surveys, usability tests, interviews, and focus groups. Users were involved in nearly every stage of device development except production. The review highlights that involving users can improve device quality and patient outcomes, but more effective involvement is needed in commercial device development. Future research should focus on the benefits and challenges of user involvement.


  • Open Access

    Towards user-centered design of medical devices for SUDEP prediction and prevention: Insights from persons with epilepsy and caregivers

    by João Ferreira, Miguel França, Mariana Rei, Ricardo Peixoto, Sidsel Armand Larsen, Adriano Bernini, Lígia Lopes, Carlos Conde, João Claro


  • Open Access

    User involvement in the design and development of medical devices in Epilepsy: a systematic review

    by João Ferreira, Ricardo Peixoto, Lígia Lopes, Sándor Beniczky, Philippe Ryvlin, Carlos Conde, João Claro

    Objective This systematic review aims to describe the involvement of persons with epilepsy (PWE), healthcare professionals (HP) and caregivers (CG) in the design and development of medical devices is epilepsy. Methods A systematic review was conducted, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligibility criteria included peer-reviewed research focusing on medical devices for epilepsy management, involving users (PWE, CG, and HP) during the MDD process. Searches were performed on PubMed, Web of Science, and Scopus, and a total of 55 relevant articles were identified and reviewed. Results From 1999 to 2023, there was a gradual increase in the number of publications related to user involvement in epilepsy medical device development (MDD), highlighting the growing interest in this field. The medical devices involved in these studies encompassed a range of seizure detection tools, healthcare information systems, vagus nerve stimulation (VNS) and electroencephalogram (EEG) technologies reflecting the emphasis on seizure detection, prediction, and prevention. PWE and CG were the primary users involved, underscoring the importance of their perspectives. Surveys, usability testing, interviews, and focus groups were the methods employed for capturing user perspectives. User involvement occurs in four out of the five stages of MDD, with production being the exception. Significance User involvement in the MDD process for epilepsy management is an emerging area of interest holding a significant promise for improving device quality and patient outcomes. This review highlights the need for broader and more effective user involvement, as it currently lags in the development of commercially available medical devices for epilepsy management. Future research should explore the benefits and barriers of user involvement to enhance medical device technologies for epilepsy. Plain Language Summary This review covers studies that have involved users in the development process of medical devices for epilepsy. The studies reported here have focused on getting input from people with epilepsy, their caregivers, and healthcare providers. These devices include tools for detecting seizures, stimulating nerves, and tracking brain activity. Most user feedback was gathered through surveys, usability tests, interviews, and focus groups. Users were involved in nearly every stage of device development except production. The review highlights that involving users can improve device quality and patient outcomes, but more effective involvement is needed in commercial device development. Future research should focus on the benefits and challenges of user involvement. Key Point Box - PWE are the users more involved in the MDD process; - Surveys and usability testing are the methods more frequently used for user involvement in the MDD process in epilepsy; - Literature only discloses the involvement of users in the MDD process of 13 commercially available medical devices for epilepsy management.


  • Open Access

    Proximity-based activation of AURORA A by MPS1 potentiates error correction

    by Nelson Leça, Francisca Barbosa, Sergi Rodriguez-Calado, Margarida Moura, Paulo D. Pedroso, Inês Pinto, Arianna E. Verza, Tanja Bange, Claudio E. Sunkel, Marin Barisic, et al.

    SUMMARY: Faithfull cell division relies on mitotic chromosomes becoming bioriented with each pair of sister kinetochores bound to microtubules oriented toward opposing spindle poles. Erroneous kinetochore-microtubule attachments often form during early mitosis, but are destabilized through the phosphorylation of outer kinetochore proteins by centromeric AURORA B kinase (ABK) and centrosomal AURORA A kinase (AAK), thus allowing for re-establishment of attachments until biorientation is achieved. MPS1-mediated phosphorylation of NDC80 has also been shown to directly weaken the kinetochore-microtubule interface in yeast. In human cells, MPS1 has been proposed to transiently accumulate at end-on attached kinetochores and phosphorylate SKA3 to promote microtubule release. Whether MPS1 directly targets NDC80 and/or promotes the activity of AURORA kinases in metazoans remains unclear. Here, we report a novel mechanism involving communication between kinetochores and centrosomes, wherein MPS1 acts upstream of AAK to promote error correction. MPS1 on pole-proximal kinetochores phosphorylates the C-lobe of AAK thereby increasing its activation at centrosomes. This proximity-based activation ensures the establishment of a robust AAK activity gradient that locally destabilizes mal-oriented kinetochores near spindle poles. Accordingly, MPS1 depletion from Drosophila cells causes severe chromosome misalignment and erroneous kinetochore-microtubule attachments, which can be rescued by tethering either MPS1 or constitutively active AAK mutants to centrosomes. Proximity-based activation of AAK by MPS1 also occurs in human cells to promote AAK-mediated phosphorylation of the NDC80 N-terminal tail. These findings uncover an MPS1-AAK cross-talk that is required for efficient error correction, showcasing the ability of kinetochores to modulate centrosome outputs to ensure proper chromosome segregation.


  • Open Access

    Role in Phenylpropanoid Biosynthesis of the Grapevine Plastidic Phosphoenolpyruvate Translocator VviPPT1

    by Angélica Silva, Henrique Noronha, Dorotea Ricci, Sarah Frusciante, Gianfranco Diretto, Carlos Conde, Antonio Granell, Hernâni Gerós

    Phosphoenolpyruvate (PEP), the main precursor of the shikimate pathway in the plastids, is imported from the cytosol through a PEP translocator (PPT). The final product of the shikimate pathway, chorismate, is the precursor for all three aromatic amino acids (AAAs), which are pivotal not only in the production of proteins but as precursors of several primary and secondary metabolites. In this study, pigmented cultured cells from cv Gamay fréaux grapes were used as a model to investigate the role of the plastidal VviPPT1 in grapevine secondary metabolism. CRISPR/Cas9-mediated knockout ofVviPPT1produced a cell line with an obvious visual low anthocyanin phenotype. Besides evident modifications of the metabolome, such as a strong reduction in phenolic acids, flavonols, and stilbenoids, key enzymes of the shikimate and phenylpropanoid pathways were inhibited at the protein activity and/or gene expression level, revealing a complex regulation of secondary metabolism not only dependent on the observed reduction of phenylalanine.